HC Wainwright Begins Coverage on Opexa Therapeutics (ACER)
Equities research analysts at HC Wainwright began coverage on shares of Opexa Therapeutics (NASDAQ:ACER) in a report released on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
Separately, ValuEngine upgraded Opexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd.
Opexa Therapeutics (NASDAQ:ACER) traded up $0.70 during trading on Wednesday, hitting $13.50. The company had a trading volume of 51,372 shares, compared to its average volume of 31,480. The company has a market cap of $94.30, a P/E ratio of -2.35 and a beta of 2.26. Opexa Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63.
Opexa Therapeutics (NASDAQ:ACER) last posted its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter.
About Opexa Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.